Long-Term Transplantation Outcomes in Patients With Primary Hyperoxaluria Type 1 Included in the European Hyperoxaluria Consortium (OxalEurope) Registry
Elisabeth L. Metry(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Justine Bacchetta(Université Claude Bernard Lyon 1), Georges Deschênes(Hôpital Robert-Debré), Graham Lipkin(Queen Elizabeth II Medical Centre), Larisa Prikhodina(Pirogov Russian National Research Medical University), Laure Collard(Centre Hospitalier Chrétien), Cécile Acquaviva(Hospices Civils de Lyon), Nilufar Mohebbi(University Hospital of Zurich), Giorgia Mandrile(University of Turin), Casper Franssen(University Medical Center Groningen), Hessel Peters‐Sengers(Amsterdam Neuroscience), Bernd Höppe(University of Bonn), Bodo B. Beck(University of Cologne), Sander F. Garrelfs(Emma Kinderziekenhuis), Markus J. Kemper(University of Zurich), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Sally‐Anne Hulton(Birmingham Children's Hospital), Pierre Cochat(Karolinska Institutet), Michiel J.S. Oosterveld(Emma Kinderziekenhuis)
Cited by 36
Related Papers
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|505
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement
|Nephrology Dialysis Transplantation|2013|472
History, epidemiology and regional diversities of urolithiasis
|Pediatric Nephrology|2008|460
COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
|Nephrology Dialysis Transplantation|2020|411